会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • Controlling Transfer of Objects Affecting Optical Characteristics
    • 控制影响光学特性的物体的传输
    • US20090156917A1
    • 2009-06-18
    • US11957610
    • 2007-12-17
    • Jorg MartiniJeffrey RoePeter KieselMichael BasslerAlan BellRichard H. BruceNoble M. Johnson
    • Jorg MartiniJeffrey RoePeter KieselMichael BasslerAlan BellRichard H. BruceNoble M. Johnson
    • A61B5/00
    • A61B5/1459A61B5/14532G01N21/03G01N21/39G01N21/8507
    • An implantable product such as an article, device, or system can include analyte and non-analyte containers in parts that can be operated as optical cavities. The product can also include fluidic components such as filter assemblies that control transfer of objects that affect or shift spectrum features or characteristics such as by shifting transmission mode peaks or reflection mode valleys, shifting phase, reducing maxima or contrast, or increasing intermediate intensity width such as full width half maximum (FWHM). Analyte, e.g. glucose molecules, can be predominantly included in a set of objects that transfer more rapidly into the analyte container than other objects, and can have a negligible or zero rate of transfer into the non-analyte container; objects that transfer more rapidly into the non-analyte container can include objects smaller than the analyte or molecules of a set of selected types, including, e.g., sodium chloride. Output light from the containers accordingly includes information about analyte.
    • 诸如制品,装置或系统的可植入产品可以包括可以作为光腔操作的部件中的分析物和非分析物容器。 该产品还可以包括流体组件,例如过滤器组件,其控制影响或移动光谱特征或特性的物体的转移,例如通过移动透射模式峰值或反射模式谷,移动相位,减小最大值或对比度,或增加中等强度宽度, 作为全宽半最大值(FWHM)。 分析物,例如 葡萄糖分子可以主要包括在一组物体中,其比其它物体更快地转移到分析物容器中,并且可以具有可忽略或零速率的转移到非分析物容器中; 将更快速地转移到非分析物容器中的物体可以包括比分析物小的物体或一组选定类型的分子,包括例如氯化钠。 因此,来自容器的输出光包括关于分析物的信息。
    • 10. 发明申请
    • System and method for monitoring of end organ oxygenation by measurement of in vivo cellular energy status
    • 通过测量体内细胞能量状态来监测末端器官氧合的系统和方法
    • US20070038126A1
    • 2007-02-15
    • US11473976
    • 2006-06-23
    • Jason PyleAlexander AravanisJeffrey RoeMyer Rosenthal
    • Jason PyleAlexander AravanisJeffrey RoeMyer Rosenthal
    • A61B6/00
    • A61B5/0059A61B5/0068A61B5/0071A61B5/0084A61B5/14556A61B5/412A61B5/413
    • A method is provided of measuring in vivo of an endogenous fluorophore in a tissue site. A known excitation wavelength of the endogenous flurophore is selected within a range of wavelengths at which the endogenous flurophore undergoes fluorescence. The tissue site is irradiated with irradiated light having at least the selected excitation wavelength within the range of wavelengths. A fluorescence emission of the tissue site resulting from the irradiation thereof is detected. A relative or absolute concentration of the endogenous fluorophore is determined by multiplying it by a calibration factor that depends one at least one of, a known excitation and emission property of the endogenous fluorophore, an intensity of the irradiated light, optical properties of an excitation probe, and specific properties of the tissue. The relative or absolute concentration of the endogenous fluorphore is used to estimate at least one of a, in vivo cellular energy production status or state of end-organ tissue oxygenation.
    • 提供了在体内测量组织部位内源性荧光团的方法。 内源荧光的已知激发波长在内源性荧光体经历荧光的波长范围内选择。 用在波长范围内至少具有选定的激发波长的照射光照射组织部位。 检测由其照射引起的组织部位的荧光发射。 内源荧光团的相对或绝对浓度通过将依赖于以下至少一个的校准因子相乘来确定:已知的内源荧光团的激发和发射性质,照射光的强度,激发探针的光学性质 ,以及组织的特定性质。 内源性荧光素的相对或绝对浓度用于估计体内细胞能量产生状态或末端器官组织氧合状态中的至少一种。